Comparing the current results to its competitors, Poseida Therapeutics Inc reported Revenue increase in the 3 quarter 2024 by 667.19 % year on year. The sales growth was above Poseida Therapeutics Inc 's competitors' average revenue growth of 13.49 %, achieved in the same quarter.
Poseida Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in the biotechnology industry, focusing on CAR-T and gene therapy sciences. It competes with larger pharmaceutical companies and academic research institutions. The company utilizes a proprietary approach that enables the inclusion of two or more fully functional CAR and/or TCR molecules into a T cell. It also develops fully allogeneic CAR-T product candidates derived from healthy donor cells for off-the-shelf use. The competitive landscape is dynamic, and the company's commercial prospects may be affected if competitors develop more effective or safer products with fewer side effects.
Due to outstanding performance in Overall company, revenue grew by 667.19 % Poseida Therapeutics Inc improved its market share, to approximately 0.38 %.
December 9, 2024
Roche s Strategic Acquisition: A Closer Look at Poseida Therapeutics Remarkable Performance Amid Tender OfferIn a significant move within the biopharmaceutical landscape, Roche Holding Ltd. has commenced a tender offer for Poseida Therapeutics, Inc. Following a previously announced merger agreement dated November 25, 2024, Roche is offering $9.00 in cash for each share of Poseida s outstanding common stock, alongside a non-tradeable contingent value right (CVR) which could yield up to an additional $4.00 per share. This acquisition not only marks a pivotal moment for both companies but also highlights Poseida’s impressive performance in a competitive market.For the third quarter of 2024, Poseida Therapeu...
CRISPR Therapeutics AG is a biopharmaceutical company focused on developing transformative gene-based medicines using its CRISPR/Cas9 gene-editing platform. They aim to leverage the potential of CRISPR to treat severe genetic diseases by directly modifying genes within the body's cells. The company collaborates with partners, conducts research and development of their therapeutics, and ultimately aims to bring their innovative treatments to market.
Century Therapeutics Inc. is a biotechnology company that aims to develop novel cell therapies targeting various diseases. Their business model focuses on leveraging induced pluripotent stem cell (iPSC) technology to engineer cellular therapies and bring them to market, with a specific emphasis on treating cancer.
Jasper Therapeutics Inc operates in the biotechnology industry, focusing on developing stem cell-based therapies for hematopoietic and immune system disorders. Their business model involves utilizing innovative stem cell technologies and partnerships within the medical community to advance their research and bring potential treatments to patients in need.
LogicBio Therapeutics Inc is a biotechnology company that focuses on developing and commercializing gene editing technology to treat rare genetic diseases.
Sources:
Poseida Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Poseida Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
